We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ALOGLC08867
Previous Study | Return to List | Next Study

Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive (ACADEMIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03794336
Recruitment Status : Completed
First Posted : January 7, 2019
Last Update Posted : April 25, 2022
Sponsor:
Information provided by (Responsible Party):
Sanofi

Brief Summary:

Primary Objectives:

  • To assess efficacy in terms of change from baseline in Hemoglobin A1c (HbA1c) at the end of study between the two drugs.
  • To assess tolerability in terms of overall Gastrointestinal (GI) tolerability for Alogliptin compared with acarbose during the whole treatment period.

Secondary Objectives:

  • To assess efficacy in terms of the percentage of patients achieving HbA1c<7%.
  • To assess efficacy in terms of percentage of patients achieving HbA1c<7% without GI effects.
  • To assess change from baseline in Fasting plasma glucose (FPG), 2-h Post plasma glucose (2-h PPG), β-cell function (HOMA-β), lipids and body weight.
  • To assess safety in terms of occurrence of hypoglycemia events.
  • To assess safety in terms of other adverse events.
  • To assess patient adherence and tolerability.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Drug: Alogliptin Drug: Acarbose Drug: Metformin Drug: Aspirin Phase 4

Detailed Description:
The duration of the study for each patient will be approximately 17 weeks consisting of about 1 week screening period and 16-week treatment period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1293 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Alogliptin vs. Acarbose in Chinese T2DM Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive: A Multicenter, Randomized, Open Label, Prospective Study
Actual Study Start Date : June 29, 2019
Actual Primary Completion Date : December 14, 2020
Actual Study Completion Date : December 14, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Medicines

Arm Intervention/treatment
Experimental: Alogliptin
Single dose of alogliptin once daily for 16 weeks
Drug: Alogliptin

Pharmaceutical form: tablet

Route of administration: oral administration

Other Name: Nesina

Drug: Metformin

Pharmaceutical form: tablet

Route of administration: oral administration


Drug: Aspirin

Pharmaceutical form: tablet

Route of administration: oral administration

Other Name: Bayaspirin

Active Comparator: Acarbose
Thrice daily dose of acarbose Dose 1 for 7 days then titrate to thrice daily dose of of acarbose Dose 2
Drug: Acarbose

Pharmaceutical form: tablet

Route of administration: oral administration

Other Name: Glucobay

Drug: Metformin

Pharmaceutical form: tablet

Route of administration: oral administration


Drug: Aspirin

Pharmaceutical form: tablet

Route of administration: oral administration

Other Name: Bayaspirin




Primary Outcome Measures :
  1. Change in Hemoglobin A1c [ Time Frame: Baseline to week 16 ]
    Change from baseline in Hemoglobin A1c at the end of study (week 16) between the two drugs

  2. Overall Gastrointestinal tolerability [ Time Frame: Baseline to week 16 ]
    Incidence of any gastrointestinal adverse events during the whole treatment period.


Secondary Outcome Measures :
  1. Percentage of patients achieving HbA1c <7% [ Time Frame: Baseline to Week 16 ]
    Percentage of patients achieving HbA1c <7% at the end of study

  2. Percentage of patients achieving HbA1c <7% without gastrointestinal effects [ Time Frame: Baseline to Week 16 ]
    Percentage of patients achieving HbA1c <7% without gastrointestinal effects at the end of study

  3. Change in Fasting Plasma Glucose (FPG) [ Time Frame: Baseline to Week 16 ]
    Change in FPG from baseline to week 16 between the two groups of drugs

  4. Occurrence of hypoglycemia events [ Time Frame: Baseline to Week 16 ]
    Number of patients reporting hypoglycemia events

  5. Other Adverse Events (AEs) [ Time Frame: Baseline to Week 16 ]
    Number of patients reporting other Adverse Events

  6. Overall tolerability [ Time Frame: Baseline to Week 16 ]
    Percentage of patients who discontinued study treatment as a result of adverse drug reaction

  7. Change in Postprandial Plasma Glucose 2-h (PPG) [ Time Frame: Baseline to Week 16 ]
    Change in PPG from baseline to week 16 between two groups of drug

  8. Change in Homeostasis model assessment-β (HOMA- β) [ Time Frame: Baseline to Week 16 ]
    Change in HOMA- β from baseline to week 16 between two groups of drug

  9. Change in Total Cholesterol (TC) [ Time Frame: Baseline to Week 16 ]
    Changes from baseline in TC to week 16 between the two groups

  10. Change in Tri Glycerides (TG) [ Time Frame: Baseline to Week 16 ]
    Changes from baseline in TG to week 16 between the two groups

  11. Change in High Density Lipoprotein-Cholesterol (HDL-C) [ Time Frame: Baseline to Week 16 ]
    Changes from baseline in HDL-C to week 16 between the two groups

  12. Change in Low Density Lipoprotein-Cholesterol (LDL-C) [ Time Frame: Baseline to Week 16 ]
    Changes from baseline in LDL-C to week 16 between the two groups.

  13. Change in body weight [ Time Frame: Baseline to Week 16 ]
    Changes from baseline in body weight to week 16 between the two groups

  14. Overall adherence to Investigational Medicinal Product (IMP) [ Time Frame: Baseline to Week 16 ]
    Calculated as overall dosing actually taken IMPs divided by the expected overall dosing as per protocol

  15. Medication possession ratio (MPR) [ Time Frame: Baseline to Week 16 ]
    Calculated as number of days actually taken IMPs divided by the expected number of days as per protocol



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

  • Type 2 Diabetes Mellitus patients (age ≥18yr) drug naive or treated with metformin monotherapy (≥1500 mg/day or individually maximally tolerated dose) for at least 12 weeks with a Hemoglobin A1c between ≥ 7.5% and ≤ 11.0% at screening.
  • Fasting plasma glucose ≤13.3mmol/L(≤240mg/dL) at screening.
  • Patients with documented history of Coronary Heart Disease (CHD) or High cardiovascular(CV) risk.
  • History of CHD, defined as previous myocardial infarction or unstable/stable angina.
  • High CV risk, defined as male or female (age> 50 yr), combined with at least one of these risk factors as below: family history of cardiovascular disease, history of hypertension, smoking, dyslipidemia, or protein urine.
  • Already treated with Aspirin or should start Aspirin treatment at physician's discretion.

Exclusion criteria:

  • Diagnosis of type 1 diabetes, diabetes resulting from pancreatic injury or secondary forms of diabetes.
  • Previous treatment with any Dipeptidyl Peptidase -4 inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonists within 1 year of screening;
  • Any contraindication of Aspirin, Dipeptidyl Peptidase- 4 inhibitor and Alpha-glucosidase inhibitor.
  • Clinically apparent liver disease or moderate /severe renal impairment or end-stage renal disease
  • Unstable CV disorder including heart failure (New York Heart Association class III or IV), refractory angina, uncontrolled arrhythmias, and severe uncontrolled hypertension (systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥105 mmHg).
  • Acute coronary syndrome event within 6 month before randomization

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03794336


Locations
Layout table for location information
China
CHINA
China, China
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Publications:
Layout table for additonal information
Responsible Party: Sanofi
ClinicalTrials.gov Identifier: NCT03794336    
Other Study ID Numbers: ALOGLC08867
U1111-1210-0679 ( Other Identifier: UTN )
First Posted: January 7, 2019    Key Record Dates
Last Update Posted: April 25, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Aspirin
Metformin
Alogliptin
Acarbose
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors